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ABStRACt
Breast cancer is one of the commonest cancers among women. Conventional therapies cause adverse side effects in 
patients. Cytokine immunotherapy such as interleukin-27 (IL-27) has been sought as an alternative cancer treatment in 
recent years. IL-27 has been shown to improve anticancer immunity and anti-angiogenesis in cancers, however, its effect 
on apoptotic and anti-apoptotic gene expression especially in breast cancers is yet to be explored. Cytotoxicity of IL-27 
in non-cancerous (184b5) and cancerous (MCF-7 and MDA-MB-231) breast cell lines was first determined for 24-72 
h in this study. The results indicated that IL-27 treatment did not retard 184b5 cell growth, however, did inhibit MCF-7 
(48 h) and MDA-MB-231 (72 h) cell growth with IC50 at 442 and 457 ng/ml, respectively. Apoptotic (TRAIL, FADD, FAS, 
caspase-3 and caspase-8) and anti-apoptotic (BCL-2, AKT, and COX-2) genes were then amplified from untreated (control) 
and treated breast cancer cells and studied. TRAIL, caspase-3, caspase-8 gene expression was significantly (p < 0.05) 
upregulated in treated MCF-7 (442 ng/ml) and MDA-MB-231 (457 ng/ml) cells. Expression of FADD and FAS genes was 
not detected in both control and treated MCF-7 and MDA-MB-231 cells. COX-2 gene was also not expressed by MCF-7 
cells, but reduced significantly (p < 0.05) in treated MDA-MB-231 cells. In MDA-MB-231 cells, IL-27 treatment seemed 
to slightly enhance the expression of AKT and BCL-2 genes which, on the other hand, was downregulated in treated 
MCF-7 cells. Conclusively, IL-27 is able to inhibit breast cancer cell growth and regulate apoptotic and anti-apoptotic 
gene expression in breast cancer cells.
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ABStRAK
Kanser payu dara adalah antara kanser yang paling biasa dihidapi oleh wanita. Rawatan konvensional menyebabkan 
kesan sampingan teruk dalam pesakit. Imunoterapi sitokin seperti interleukin-27 (IL-27) telah digunakan sebagai 
rawatan alternatif sejak kebelakangan ini. IL-27 telah terbukti dapat menambah baik imuniti antikanser dan aktiviti 
anti-angiogenesis dalam kanser, namun kesannya pada pengekspresan gen apoptotik and anti-apoptotik terutamanya 
pada kanser payu dara masih belum diterokai. Dalam kajian ini, kesan sitotoksisiti IL-27 pada sel selanjar bukan kanser 
(184b5) dan kanser (MCF-7 dan MDA-MB-231) ditentukan pada 24-72 jam dalam kajian ini. Dapatan kajian menunjukkan 
rawatan IL-27 tidak menjejaskan pertumbuhan sel 184b5, namun menghalang pertumbuhan sel MCF-7 (48 jam) and 
MDA-MB-231 (72 jam) dengan nilai IC50 ialah 442 and 457 ng/ml, masing-masing. Gen apoptotik (TRAIL, FADD, FAS, 
caspase-3 dan caspase-8) and anti-apoptotik (BCL-2, AKT, dan COX-2) kemudiannya diamplifikasikan daripada sel kanser 
payu dara kawalan dan terawat serta dikaji. Pengekspresan gen TRAIL, caspase-3 dan caspase-8 telah meningkat secara 
signifikan (p < 0.05) dalam sel MCF-7 (442 ng/ml) and MDA-MB-231 (457 ng/ml) yang dirawat. Pengekspresan gen 
FADD dan FAS gagal dikesan dalam sel MCF-7 dan MDA-MB-231, mahupun sel kawalan atau terawat. Gen COX-2 tidak 
diekspreskan oleh sel MCF-7 tetapi pengekspresannya telah menurun secara signifikan (p < 0.05) dalam sel MDA-MB-
231 yang dirawat. Dalam sel MDA-MB-231, rawatan IL-27 meningkatkan pengekspresan gen AKT dan BCL-2, namun 
pengekspresan kedua-dua gen tersebut telah menurun dalam sel MCF-7 yang dirawat. Kesimpulannya, IL-27 dapat 
menghalang pertumbuhan sel kanser payu dara dan mengawal atur pengekspresan gen apoptotik and anti-apoptotik 
dalam sel kanser payu dara.
Kata kunci: IL-27; imunoterapi sitokin; kanser payu dara negatif-ganda tiga; kanser duktus payu dara invasif
IntRODuCtIOn
Breast cancer accounts for 32.1% death among cancer 
patients in Malaysia (Azizah et al. 2016). Among all 
breast cancer cases, 10-20% of cases are triple negative 
breast cancer (tnBC) meanwhile 70-80% of breast cancers 
constitute of invasive ductal carcinoma (IDC) (tommiska et 
al. 2007). Compared to IDC, tnBC is characterized by the 
absence of estrogen, progesterone and human epidermal 
growth receptors (Dent et al. 2007). It is, therefore, more 
aggressive and could readily metastasize to the other vital 
organs such as liver, brain and lung (Carey et al. 2010). 
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Conventional treatments such as chemotherapy and surgery 
have successfully increased breast cancer patients’ life 
span (Isakoff 2010), however, they, at the same time, 
cause tremendous adverse side effects in patients such as 
immunosuppression, congestive heart failure, leukemia 
(Pan et al. 2014), emotional breakdown and depression due 
to physical changes (Arroyo & Lopez 2010). Owing to the 
shortcomings of currently available treatments for breast 
cancers, Stagg & Allard (2013) suggested that cytokine 
immunotherapy could be eligible alternative for treating 
breast cancer patients with negligible or minimal adverse 
effects. Cytokines can inhibit progression of cancer cells 
by augmenting anticancer immunity meanwhile promoting 
production of anti-angiogenic proteins such as IFN-γ and 
monokines (Shimizu et al. 2006). Such encouraging effects 
have been proven in a few clinical trials using aldesleukin 
(Interleukin 2, IL-2), protein CSPG4 and nY-ESO-1 
(Ademuyiwa et al. 2012; Wang et al. 2010; Roberti et al. 
2011) on breast cancer patients. Although these cytokines 
possessed effective anti-breast cancer activities, some 
recipients still experienced side effects such as fever, low 
platelet and white blood cells counts (Rosenberg et al. 2011; 
Sharma et al. 2011). to help address the concern, the use 
of interleukin-27 (IL-27) that has been proven to prohibit 
colon cancer and myeloma growth was proposed (ho et 
al. 2009). IL-27 treatment has triggered very minimal side 
effects in preclinical trials using rat models (Yoshimoto 
et al. 2015). IL-27 is a heterodimeric cytokine that is 
composed of two protein subunits, Epstein-Barr virus gen 
induced-3 (EBVI-3) and p28 (Pflanz et al. 2002). Zarghi 
& Arfaei (2011) demonstrated that IL-27 was able to 
undermine the expression of anti-apoptotic factors such 
as COX-2 and PGE-2 in cancer cells. Besides, IL-27 also 
upregulates the protein expression level of interferon 
gamma (IFN-γ) which in turn triggers the production of 
apoptotic proteins such as caspases (Ruiz-Ruiz, Muñoz-
Pinedo & López-Rivas 2000) that induce programmed 
cancer cell death.
Despite the proven anti-angiogenic effects and 
enhancement of anticancer immunity by IL-27, explicit 
regulatory effects of IL-27 on the expression of apoptotic 
and anti-apoptotic genes particularly in breast cancers are 
barely available. In view of this, the current study aimed 
to investigate the cytotoxicity, regulation of apoptotic 
and anti-apoptotic gene expression by IL-27 in MCF-7 
and MDA-MB-231 breast cancer cell lines. the results 
indicated that IL-27 was able to obstruct breast cancer cell 
growth and regulate the expression of apoptotic and anti-
apoptotic genes, hence, a potential candidate for cytokine 
immunotherapy in treating breast cancers.
MAtERIALS AnD MEthODS
CELLS AnD IL-27
Breast cancer cell lines, MDA-MB-231 and MCF-7 and 
non-cancerous breast cell line, 184b5 were purchased 
from American type Culture Collection (AtCC) and were 
maintained in MEM medium (Sigma-Alrich, St. Louis, uSA) 
supplemented with 10% (v/v) fetal bovine serum (Sigma-
Aldrich, St Louis, uSA) and 50 μg/ml PenStrep antibiotics 
(Sigma-Aldrich, St Louis, uSA). Cells were grown at 37°C 
in a 5% CO2 incubator. Interleukin-27 (IL-27) (Sigma-
Aldrich, St. Louis, uSA) was prepared as 10 µg/ml stock 
with nuclease-free water and then serially diluted to 50-500 
ng/ml with MEM medium.
CYtOtOXICItY OF IL-27 In nOn-CAnCEROuS AnD 
CAnCEROuS BREASt CELL LInES
Cytotoxicity of IL-27 in 184b5, MDA-MB-231 and MCF-7 
cells was determined by using MtS [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-
tetrazolium, inner salt] assay kit (Celltiter 96® AQueous 
One Solution Cell Proliferation Assay) (Sigma-Aldrich, St 
Louis, uSA). Cells (2 × 105 cells/ml) were cultured on 96-
well plates and incubated overnight at 37°C under 5% CO2. 
Cells were then washed three times with PBS and 50-500 
ng/ml of IL-27 (Canale et al. 2011) was added to the cells 
in triplicate. non-treated cells were prepared as negative 
control. IL-27 treatment was carried out for 24, 48, and 72 
h. At each designated time point, the plate was collected and 
media was removed. Cells were washed with PBS and 100 
μl fresh MEM medium was added to the cells. About 20 μl 
of Celltiter 96® AQueous One Solution reagent was added 
into each well and the cells were further incubated for 3 h at 
37°C under 5% CO2. the plate was read at 570 nm. Dose-
response curve was conducted by using the absorbance 
readings. the value of 50% inhibitory concentration (IC50) 
of IL-27 was derived from the curve.
ISOLAtIOn OF tOtAL RnA
to allow collection of cells at larger number, MDA-MB-
231 and MCF-7 cells (3 × 105 cells/ml) were cultured on a 
6-well plate at 37°C under 5% CO2 until 80% confluency 
was achieved. MCF-7 and MDA-MB-231 cells were 
treated with IL-27 at IC50 in duplicate for 48 and 72 
h, respectively. After the treatment, the total RnA was 
extracted from the samples by using tRIzol RnA reagent 
(Invitrogen, new York, uSA) as described in tan, hassan 
& Yap (2016). the extracted total RnA (250 ng) was used 
to generate cDnA using M-MLV reverse transcriptase 
(Promega Inc, Madison, uSA).
AMPLIFICAtIOn OF APOPtOtIC AnD AntI-APOPtOtIC 
GEnES
Polymerase chain reaction (PCR) was carried out using 
Gotaq Plus DnA polymerase kit (Lucigen, Middleton, uSA) 
according to the manufacturer’s instructions. Apoptotic 
genes such as TRAIL, FADD, FAS, caspase-3 and caspase-8 
and anti-apoptotic genes such as COX-2, BCL-2 and AKT 
were amplified from untreated and treated breast cancer 
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cells. Primers used in the PCR amplification are shown 
in table 1. GAPDH served as a housekeeping gene in this 
study. thermal cycling conditions were as follows: initial 
denaturation: 95°C for 120 s, 30 cycles of denaturation at 
95°C for 60 s, annealing at 55°C for 60 s and extension 
at 72°C for 60 s, final extension at 72°C for 300 s and 
the products were finally stored at 4°C. the PCR products 
were mixed with 6X DnA loading dye (Cleaver Scientific, 
Warwickshire, uK) and analysed on 1% (w/v) agarose gel 
at 70 V for 45 min. the agarose gel was then observed 
under a uV transilluminator box (Bio-Rad, California, 
uSA). Gel pictures were captured and intensity of PCR 
products was analyzed using Image J (http://imagej.nih.
gov). the intensity was measured and expressed as relative 
expression level to that of GADPH.
StAtIStICAL AnALYSIS
Experiments were carried out in duplicate or triplicate. Data 
were expressed as mean + S.D. Data were also analyzed 
with GraphPad Prism version 7.0. non-linear regression 
test was used to determine the IC50 of the IL-27 in cancerous 
breast cells. unpaired t-test was used to compare the gene 
expression levels in non-treated and treated breast cancer 
cells.
RESuLtS
CYtOtOXICItY OF IL-27 In nOn-CAnCEROuS AnD BREASt 
CAnCER CELL LInES
IL-27 treatment for 24 h did not affect the growth of non-
cancerous, 184b5 and cancerous breast cells, MCF-7 and 
MDA-MB-231 (Figure 1a). MCF-7 breast cancer cells 
exhibited 100% viability while 184b5 breast cells remained 
growing in the range of 80 to 100%. Although slightly 
affected at higher concentrations of IL-27, MDA-MB-231 
cells was still able to maintain at least 90% viability.
Figure 1(b) shows the effects of IL-27 treatment on the 
viability of the cells for 48 h. the viability of 184b5 and 
MDA-MB-231 remained relatively stable and unchanged 
which cell viability was at least 80%. however, a much 
lower viability was observed in MCF-7 breast cancer cell 
line especially when treated with 500 ng/ml of IL-27. the 
cell viability was only retained at 10%. Based on the curve, 
IC50 of IL-27 in MCF-7 was determined at 442 ng/ml.
As IL-27 treatment progressed to 72 h, none of the 
MCF-7 cells survived the treatment while 184b5 cells still 
did not exhibit any signs of toxicity from the treatment 
(Figure 1C). For MDA-MB-231 cells treated with IL-27 
at 200-500 ng/ml, cell viability declined gradually in a 
concentration-dependent pattern. the cell viability was 
less than 50% after being treated with IL-27 at 500 ng/ml 
for 72 h, hence the IC50 of 457 ng/ml. 
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FIGuRE 1. Cytotoxicity results of IL-27 treatment in non-cancerous and cancerous breast cell lines. 184b5, MCF-7 and MDA-MB-
231 cells were treated with IL-27 for (A) 24 h; (B) 48 h; and (C) 72 h. Cell viability was determined using MtS assay kit.
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REGuLAtIOn OF APOPtOtIC AnD AntI-APOPtOtIC GEnE 
EXPRESSIOn BY IL-27 In MCF-7 AnD MDA-MB-231 BREASt 
CAnCER CELL LInES
MCF-7 (442 ng/ml) and MDA-MB-231 (457 ng/ml) 
cells were first treated with IL-27 at IC50 for 48 and 72 
h, respectively. the effects of IL-27 treatment on the 
expression levels of apoptotic and anti-apoptotic genes 
were analyzed using PCR. As shown in Figure 2A and 2B, 
IL-27 treatment upregulated gene expression of TRAIL, 
caspase-3 and caspase-8 in both MCF-7 and MDA-MB-
231 cell lines. nevertheless, treatment with IL-27 was 
unable to upregulate the expression of FAS and FADD genes 
in the breast cancer cells.
Regulation of anti-apoptotic gene expression in 
MCF-7 and MDA-MB-231 breast cancer cells by IL-
27 was also investigated in this study. In MCF-7 cells, 
expression of AKT and BCL-2 genes decreased following 
IL-27 treatment (Figure 2C). however, the interleukin 
treatment seemed to slightly increase the expression of 
AKT and BCL-2 genes in MDA-MB-231 cells (Figure 2D). 
COX-2 gene was expressed minimally by untreated MDA-
MB-231 cells. the gene expression was then suppressed 
by a 72-h treatment with IL-27 (Figure 2D). unlike that 
observed in untreated and treated MDA-MB-231 cells, the 
COX-2 gene expression was not detected in both untreated 
and treated MCF-7 cells.
A
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FIGuRE 2. Expression of apoptotic and anti-apoptotic genes in non-treated and IL-27-treated breast cancer cells was analyzed on 
1% (w/v) agarose gel. Panels: (A) expression of apoptotic genes in MCF-7; (B) expression of apoptotic genes in MDA-MB-231; 
(C) expression of anti-apoptotic genes in MCF-7; and (D) expression of anti-apoptotic genes in MDA-MB231. Symbols (+) and (-) 
indicate treated and non-treated samples, respectively.
Regulation of apoptotic and anti-apoptotic gene 
expression by IL-27 in breast cancer cells was further 
estimated by comparing the expression levels of those 
genes with the expression level of the housekeeping gene, 
GADPH. Based on Figure 3A, IL-27 treatment successfully 
upregulated the gene expression levels of TRAIL (0.7), 
caspase-3 (0.7) and caspase-8 (0.6) significantly (p < 
0.05) in treated MCF-7 cells compared to that of non-
treated samples (undetectable). In MDA-MB-231 cells 
(Figure 3B), IL-27 treatment had managed to increase the 
relative gene expression levels of caspase-3 (0.3 to 1.6) 
and caspase-8 (undetectable to 1.8) significantly (p < 0.05). 
the relative gene expression level of TRAIL in IL-27-treated 
MDA-MB-231 cells also showed some level of increment 
(almost 1.2), however, the upregulation was not statistically 
significant enough (p > 0.05) when compared with that of 
non-treated cells.
As shown in Figure 3C, the relative gene expression 
level of AKT in MCF-7 cells declined from 0.7 to 0.6 
after being treated with IL-27. the reduction was not 
statistically significant (p > 0.05). Similarly, the relative 
gene expression level of BCL-2 in MCF-7 cells was also 
not significantly (p > 0.05) affected by IL-27 treatment. the 
relative gene expression level decreased from 0.4 to 0.3.
It is noteworthy that IL-27 treatment had, on the other 
hand, upregulated (p < 0.05) the relative expression levels 
of AKT and BCL-2 in MDA-MB-231 cells (Figure 3D). 
unlike the AKT and BCL-2 genes, COX-2 gene expression 
was somewhat inhibited significantly (p < 0.05) by IL-27 
in MDA-MB-231 cells.
DISCuSSIOn
Breast cancer is the one of most severe cancers affecting 
women globally (WhO 2014). According to statistics by the 
International Agency for Research on Cancer, Malaysia has 
38.7% breast cancer incidence rate with 5410 new cases 
in 2012 alone (Yip, Pathy & teo 2014). norsaadah et al. 
(2005) explained that the increased risk of breast cancers 
among Malaysian women is mainly due to lifestyle and 
hereditary genetic factors. Chemotherapy, radiotherapy 
and mastectomy have long been used in breast cancer 
treatments (Wijayahadi et al. 2007). Although effective, 
these therapies nevertheless cause adverse side effects 
such as ovarian failure (tiong et al. 2014) and neutropenia 
(Phua et al. 2012) in cancer patients. therefore, tan & Lota 
(2008) proposed immunotherapy as a novel therapeutic 
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FIGuRE 3. Relative gene expression levels of apoptotic genes in (A) MCF-7 cells; (B) MDA-MB-231 cells; and anti-apoptotic 
genes in (C) MCF-7 cells; (D) MDA-MB-231 cells. the relative gene expression levels were measured in relative to the basal gene 
expression level of GADPH. Symbol * represents the significance level (p < 0.05) in relative to the negative control.
tABLE 1. Primer sets used for the amplification of apoptotic and anti-apoptotic genes
  Genes      Forward primers      Reverse primers   References
 TRAIL  5’ – GGAtCAtGGCtAtGAtGGAG – 3’ 5’ – GCGGCCGCAGttAGCCAACtAA Li et al. 2003
   AAAGGC – 3’ 
 FAS 5’ – GGAGGAttGCtCAACAACCAt – 3’ 5’ – CAttGtCAttCttGAtCtCAtCt Shen et al. 2002
   Attt- 3’ 
 FADD 5’ – AtG GAC CCG ttC CtG GtG Ct – 3’ 5’ – tCA GGA CGC ttC GGA GGt Yamada et al. 2014
   AGA – 3’ 
 Caspase-3 5’ – ttAAtAAAGGtAtCCAtGGAGAA 5’ – ttAGtGAtAAAAAtAGAGttCttt Devarajan et al. 2002
  CACt – 3’ tGtGAG – 3’ 
 Caspase-8 5’ – AGAGtCtGtGCCCAAAtCAAC – 3’ 5’ – GCtGCttCtCtCtttGCtGAA – 3’ Borhani et al. 2014
 COX-2 5’ – tCCAAAtGAGAttGtGGGAAAAt 5’- AGAtCAtCtCtGCCtGAGtAtCtt Ochiai et al. 1999
  tGCt – 3’  – 3’ 
 AKT 5’ – tCtAtGGCGCtGAGAG – 3’ 5’ – CttAAtGtGCCCGtCCtt– 3’ Zhang et al. 2013
 BCL-2 5’ – ACt tGt GGC CCA GAt AGG CAC  5’ – CGA Ctt CGC CGA GAt GtC CAG Dong et al. 1999
  CCA G – 3’ CCA G – 3’ 
 GADPH 5’ – AAGGtGAAGGtCGGAGtCAAC – 3’ 5’ – GGGGtCAttGAtGGCAACAAtA – 3’ Borhani et al. 2014
strategy for breast cancer treatment. Immunotherapy 
stimulates specific anticancer immune cells that destroy 
and inhibit cancer cell growth without affecting the normal 
cells (Pflanz et al. 2002). In recent years, anticancer effects 
of cytokines have been widely studied as these signaling 
peptides are believed to be useful for immunotherapy 
especially in terms of enhancing anticancer immunity 
and, at the same time, activate immune responses that 
prohibit cancer cells from proliferating uncontrollably 
(Lee & Margolin 2011). As a member of cytokines with 
potent anticancer effects, IL-27 has been shown to inhibit 
anti-angiogenesis which in turns induces cancer cell death 
without causing inflammation and toxicity to normal cells 
(Lucas et al. 2003). For this reason, cytotoxicity, regulation 
of apoptotic and anti-apoptotic gene expression by IL-27 
in breast cancers were studied using MDA-MB-231 and 
MCF-7 breast cancer cell lines in this study.
MCF-7 breast cancer cell line represented the major 
type (invasive ductal cancer, IDC) of breast cancers that is 
commonly found in breast cancer patients. IDC accounts 
for almost 80% of breast cancer incidences (Martinez 
& Azzopardi 1979). MDA-MB-231, on the other hand, 
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represented the aggressive, metastatic breast cancer that is 
responsible for approximately 20% of breast cancer cases 
(tommiska et al. 2007).
Since there were no empirical data on cytotoxicity of 
IL-27 in non-cancerous and cancerous breast cell lines, the 
cytotoxicity assay was first performed at the concentration 
range of 50-500 ng/ml in order to determine the IC50 of IL-
27 in both non-cancerous and cancerous breast cell lines. 
the concentration range was chosen according to Canale et 
al. (2011) that showed any IL-27 concentrations below 100 
ng/ml did not significantly inhibit the growth of leukemic 
cells in acute B-lymphoma for 24 to 48 h of treatment. 
Even with increasing concentrations, anti-leukemic effects 
of IL-27 could only be observed at 200 ng/ml after 72 h 
of treatment. In this light, the concentration range of IL-
27 was set at 50-500 ng/ml while IL-27 treatment was 
performed from 24-72 h in this study. the results showed 
that IL-27 treatment did not exert adverse toxic effects on 
non-cancerous breast cells, 184b5 but managed to inhibit 
more than 50% of MCF-7 and MDA-MB-231 breast cancer 
cell growth after 48- and 72-h treatments, respectively. this 
finding is in line with Dong et al. (2016) in which IL-27 was 
shown to be able to exert significant cytotoxicity to A549 
lung carcinoma cells after 48 h of treatment. Besides, the 
cytotoxicity of IL-27 in both cancer cell lines also increased 
in a concentration-dependent manner. this observation is 
similar to that reported by Cocco et al. (2010). Compared 
to MCF-7 cells, IL-27 required longer duration in triggering 
MDA-MB-231 cell death. this is most likely because 
MDA-MB-231 is highly aggressive and resistant to 
treatment due to its triple-negative characteristics (Di Carlo 
et al. 2014). It was found that highly anticancer-resistant 
cancers would require treatment duration as long as 120 h 
for IL-27 to exert it cytotoxic effects on the cancer cells. 
Chiba et al. (2013) demonstrated that IL-27 treatment 
was able to inhibit melanoma growth by regulating tRAIL 
pathway. upregulation of TRAIL gene in both MCF-7 and 
MDA-MB-231 cells by IL-27 in this study correlates 
well with findings in that report. By enhancing tRAIL 
expression in cancer cells, apoptosis occurs and results 
in cancer cell death through activation of caspases such 
as caspase-3 and -8 (Wang & El Deiry 2003). Caspase-3 
and -8 gene expression levels in breast cancer cells were 
found increased by IL-27 treatment in this study. this 
result supports findings by tang, Lahti and Kidd (2000) 
in which caspase-3 activation was an important key for 
the generation of functional caspase-8 in MCF-7 cells. 
In view of this, together with upregulation of tRAIL gene 
expression, it is probable that IL-27 induced cell death in 
MCF-7 and MDA-MB-231 via tRAIL/caspase 3/caspase 
8 pathway.
Expression of FAS and FADD genes was not affected 
by IL-27 treatment in both of the breast cancer cell lines. 
Previous findings showed that MCF-7 and MDA-MB-231 
breast cancer cells were less responsive to FAS and FADD 
gene expression even when treated with anti-cancer agents 
such as IFN-γ at 10 times higher concentration (Keane et 
al. 1996; Mullauer et al. 2000). Furthermore, Day, huang 
& Safa (2008) reported the presence of FAS and FADD 
inhibitor, namely cellular-Flic inhibitory protein (c-FLIP) 
in MCF-7 cells, hence significantly low FAS and FADD 
gene expression in the breast cancer cells. however, this 
speculation requires further empirical authentication.
IL-27 treatment slightly lowered AKT and BCL-2 gene 
expression in MCF-7 cells in this study. Reduction of AKT 
and BCL-2 gene expression had been shown to speed up 
melanoma cell death through anti-angiogenesis (Cocco 
et al. 2010) and apoptosis in cancer cells by release of 
cytochrome-c (Cory, huang & Adams 2003). Youle & 
Strasser (2008) also found that it is important for breast 
cancer cells to maintain high BCL-2 level in order to sustain 
their growth. therefore, a slight reduction of BCL-2 level 
could wreak dramatic change such as cell death in breast 
cancer cells as seen in this study.
unlike MCF-7 breast cancer cells, the gene expression 
levels of AKT and BCL-2 were somehow upregulated by 
IL-27 in MDA-MB-231 cells. A similar observation was 
reported by Chen et al. (2001). In the report, it was clearly 
demonstrated that even if the anti-apoptotic genes were 
upregulated in cancer cells, the relatively high expression 
level of TRAIL gene was able to block their anti-apoptotic 
activities hence cancer cell death. Besides, although 
often regarded as an anti-apoptotic gene, BCL-2 is also 
responsible for the activation of certain apoptotic molecules 
such as BAX and BAD, therefore leading to cancer cell death 
(Delbridge et al. 2016) as observed in IL-27 treated MDA-
MB-231 cells in this study. It is noteworthy that further 
laboratory investigations are required to authenticate these 
speculations rigorously.
half et al. (2002) indicated that COX-2 gene 
expression was commonly knocked down in MCF-7 but 
not in MDA-MB-231 cells. the COX-2 gene expression 
was downregulated by IL-27 treatment in MDA-MB-231 
cells. the inhibition could possibly occur StAt-1 pathway 
that eventually causes cell death (tsatsanis et al. 2006).
COnCLuSIOn
Although this study presents preliminary evidence on 
cytotoxicity of IL-27 in non-cancerous and cancerous 
breast cell lines, it offers vital information on the potential 
use of IL-27 in treating breast cancers without causing 
much side effects to patients. Early evidence describing 
how IL-27 regulates apoptotic and anti-apoptotic gene 
expression in breast cancer cells, on the other hand, provide 
important insight for further laboratory investigations so 
IL-27 can be used more specifically and precisely as a 
potential anti-breast cancer cytokine. Conclusively, IL-
27 holds promise as a potential interleukin candidate in 
cytokine immunotherapy for breast cancers.
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